Publications by authors named "P Gravel"
Article Synopsis
- Quantitative molecular imaging using PET is vital for understanding brain disorders, and the newly developed NeuroEXPLORER system enhances imaging quality with improved spatial resolution and sensitivity.
- The study assessed the NeuroEXPLORER's quantitative precision and accuracy using various phantom and human data, focusing on critical imaging conditions for dynamic neuroimaging.
- Results indicated that the NeuroEXPLORER maintained high accuracy in quantifying brain activity and showed minimal biases, making it suitable for short-frame reconstructions in neuroimaging studies.
Article Synopsis
- The study investigates synaptic density in autistic adults using positron emission tomography (PET) and synaptic vesicle glycoprotein 2A (SV2A) as a marker.
- Results show that autistic individuals exhibit a 17% lower synaptic density across the whole cortex compared to non-autistic peers, with significant deficits in various brain regions, especially the prefrontal cortex.
- The findings suggest that lower synaptic density is associated with increased autistic features, pointing to a potential molecular basis for autism that requires further exploration.
Real-World Evidence (RWE), which has historically been used to support post-approval safety studies, has recently gained acceptance for new drug applications as supportive evidence or as new clinical evidence for medicinal products with orphan designation and/or in disease areas with high unmet need. Here, we present a case study for the use of RWE in the approval of abaloparatide in the European Union (EU) under the tradename Eladynos. In addition to data from the pivotal Phase 3 study, the marketing authorization application (MAA) included clinical data from additional interventional and observational studies, as well as post-marketing data obtained from the United States (US) market since approval of abaloparatide by the Food and Drug Administration (FDA) in 2017.
View Article and Find Full Text PDFHead motion correction (MC) is an essential process in brain positron emission tomography (PET) imaging. We have used the Polaris Vicra, an optical hardware-based motion tracking (HMT) device, for PET head MC. However, this requires attachment of a marker to the subject's head.
View Article and Find Full Text PDFBackground: Positron emission tomography (PET) work with the dopamine D3 receptor (DR) preferring ligand [C]PHNO in obese individuals has demonstrated higher binding and positive correlations with body mass index (BMI) in otherwise healthy individuals. These findings implicated brain reward areas including the substantia nigra/ventral tegmental area (SN/VTA) and pallidum. In cocaine use disorder (CUD), similar SN/VTA binding profiles have been found compared to healthy control subjects.
View Article and Find Full Text PDF